COM:CNSPHARMA
CNS Pharmaceuticals, Inc.
- Stock
Last Close
0.13
22/11 21:00
Market Cap
1.52M
Beta: -
Volume Today
194.47K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | ||||||||
average payables | 93.18K - | 209.18K 124.49% | 617.91K 195.40% | 1.23M 99.80% | 2.60M 110.79% | 1.84M 29.26% | ||
average receivables | ||||||||
book value per share | -1.25 - | 16.71 1,435.64% | 25.18 50.70% | 7.54 70.06% | 5.97 20.77% | -1.18 119.70% | ||
capex per share | -0.04 - | -0.03 26.75% | -0.01 79.80% | -0.00 50.37% | -0.00 68.11% | |||
capex to depreciation | -10.29 - | -1.62 84.29% | -0.44 72.81% | -0.38 14.47% | -0.94 150.87% | |||
capex to operating cash flow | 0.01 - | 0.00 56.69% | 0.00 82.69% | 0.00 1.35% | 0.00 34.13% | |||
capex to revenue | ||||||||
cash per share | 0.64 - | 15.92 2,372.06% | 25.34 59.22% | 5.70 77.52% | 7.38 29.62% | 0.15 98.03% | ||
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | ||||||||
debt to assets | 0.75 - | 0.46 38.25% | 0.03 - | 0.04 59.81% | 0.03 29.07% | 0.18 463.10% | ||
debt to equity | -2.08 - | -0.58 72.28% | 0.03 - | 0.06 85.94% | 0.05 13.92% | -0.07 234.64% | ||
dividend yield | ||||||||
earnings yield | -0.12 - | -0.07 40.79% | -0.32 339.91% | -0.76 137.38% | -4.68 515.85% | -3.94 15.74% | ||
enterprise value | 11.28K - | 60.24M 533,807.80% | 46.67M 22.52% | 15.98M 65.76% | 13.88M 13.12% | -6.38M 145.93% | 4.54M 171.14% | |
enterprise value over ebitda | -8.20 - | -12.18 48.47% | -1.69 86.10% | -0.99 41.46% | 0.42 142.20% | -0.24 157.53% | ||
ev to operating cash flow | -84.08 - | -13.13 84.38% | -2.18 83.37% | -1.03 53.04% | 0.60 158.90% | -0.32 153.12% | ||
ev to sales | ||||||||
free cash flow per share | -1.63 - | -7.86 381.48% | -13.24 68.59% | -15.42 16.43% | -7.76 49.69% | -3.75 51.60% | ||
free cash flow yield | -0.01 - | -0.07 457.06% | -0.25 274.11% | -0.73 195.21% | -3.23 341.44% | -2.96 8.53% | ||
graham net net | -2.16 - | 15.23 804.21% | 21.90 43.79% | 3.27 85.09% | 3.77 15.46% | -1.48 139.31% | ||
graham number | 21.77 - | 56.91 161.45% | 98.37 72.84% | 52.08 47.06% | 38.83 25.43% | 11.51 70.36% | ||
income quality | 0.10 - | 0.92 845.68% | 0.77 15.58% | 0.96 24.65% | 0.69 28.33% | 0.75 8.52% | ||
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -18.88 - | -86.65 358.89% | -2.90K 3,242.82% | -1.51K 47.84% | -2.17K 43.81% | 1.37K 162.90% | ||
interest debt per share | 0.83 - | 0.10 88.26% | 0.80 721.66% | 0.45 43.42% | 0.31 32.26% | 0.08 75.12% | ||
inventory turnover | ||||||||
invested capital | -2.08 - | -0.58 72.28% | 0.03 - | 0.06 85.94% | 0.05 13.92% | -0.07 234.64% | ||
market cap | 60.20M - | 53.91M 10.45% | 29.58M 45.13% | 18.50M 37.46% | 3.27M 82.33% | 4.78M 46.40% | ||
net current asset value | -58.53K - | -644.50K 1,001.10% | 7.58M 1,276.56% | 13.59M 79.22% | 5.34M 60.69% | 7.64M 43.10% | -4.54M 159.41% | |
net debt to ebitda | -0.00 - | 1.89 40,696.25% | 1.44 23.77% | 0.33 77.13% | 0.63 91.93% | 0.01 97.92% | ||
net income per share | -16.83 - | -8.62 48.82% | -17.08 98.24% | -15.99 6.38% | -11.22 29.82% | -5.00 55.41% | ||
operating cash flow per share | -1.63 - | -7.81 378.77% | -13.21 69.13% | -15.41 16.66% | -7.75 49.69% | -3.75 51.59% | ||
payables turnover | ||||||||
receivables turnover | ||||||||
research and ddevelopement to revenue | ||||||||
return on tangible assets | -10.82 - | -0.50 95.42% | -0.60 20.47% | -1.60 168.75% | -1.17 27.01% | -11.08 846.74% | ||
revenue per share | ||||||||
roe | 13.46 - | -0.52 103.83% | -0.68 31.55% | -2.12 212.71% | -1.88 11.42% | 4.25 326.37% | ||
roic | 3.82 - | -0.51 113.35% | -0.66 28.96% | -2.00 204.62% | -1.79 10.71% | 4.57 355.40% | ||
sales general and administrative to revenue | ||||||||
shareholders equity per share | -1.25 - | 16.71 1,435.64% | 25.18 50.70% | 7.54 70.06% | 5.97 20.77% | -1.18 119.70% | ||
stock based compensation to revenue | ||||||||
tangible asset value | -58.53K - | -549.30K 838.46% | 7.60M 1,483.78% | 13.95M 83.50% | 6.62M 52.52% | 8.13M 22.82% | -4.43M 154.50% | |
tangible book value per share | -1.25 - | 16.71 1,435.64% | 25.18 50.70% | 7.54 70.06% | 5.97 20.77% | -1.18 119.70% | ||
working capital | -58.53K - | -644.50K 1,001.10% | 7.58M 1,276.56% | 13.59M 79.22% | 5.34M 60.69% | 7.64M 43.10% | -4.54M 159.41% |
All numbers in USD (except ratios and percentages)